The proteasome inhibitor bortezomib (BOR) has shown to modulate the c-KIT-associated apoptosis cascade in leukemia cells by directly inducing c-KIT internalization and lysosome-induced degradation (42). The gene discussed is KIT; the disease is leukemia.